Project description:The co-cultivation investigation showed that A. cornea TBRC 12900 co-cultivated with P. mangrovi TBRC-BCC 42794 showed a high level of A. cornea mycelial growth. Proteomics analysis was employed to reveal predicted biological activities involved in the mutualistic relationship between the two strains during mycelial growth.
Project description:Gram-negative bacteria are an emerging source of natural products with pharmaceutical potential. However, the limited availability of essential genetic tools for drug discovery and sustainable production remains a challenge. Burkholderia serves as a promising source for such tools, as it produces diverse natural products and can be experimentally manipulated in the laboratory. Hence, this study aimed to identify strong and constitutive promoters from Burkholderia stagnalis TBRC 18363 for unlocking the potential of cryptic biosynthetic genes and enhance natural product production. Highly expressed genes were identified through transcriptomic analysis. Twenty-six promoters were evaluated in Escherichia coli and Pseudomonas putida reporter systems. Among all, promoters p2035 and p5642 exhibited superior performance in both systems. These promoters were selected for further investigation and were found to enhance the production titer of icosalide in B. stagnalis TBRC 18363 and FR900359, a Gq/11 protein inhibitor depsipeptide, in Chromobacterium vaccinii. This research emphasizes efficient promoters for target gene overexpression in Gram-negative bacteria.
Project description:Primary objectives: The primary objective is to investigate circulating tumor DNA (ctDNA) via deep sequencing for mutation detection and by whole genome sequencing for copy number analyses before start (baseline) with regorafenib and at defined time points during administration of regorafenib for treatment efficacy in colorectal cancer patients in terms of overall survival (OS).
Primary endpoints: circulating tumor DNA (ctDNA) via deep sequencing for mutation detection and by whole genome sequencing for copy number analyses before start (baseline) with regorafenib and at defined time points during administration of regorafenib for treatment efficacy in colorectal cancer patients in terms of overall survival (OS).
